Phase 2 Clinical Trial of Rhu-pGSNThe study, “Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers,” NCT06216366 is being conducted under a contract with the Office of Naval Research with the University of Maryland. The study is designed to assess the impact of rhu-pGSN on key inflammatory responses and microparticle production associated with decompression. Previous studies have shown that individuals with DCS exhibit depleted levels of plasma gelsolin and elevated levels of microparticles that contain inflammatory cytokines. The study will assess a broad range of outcomes including plasma gelsolin levels, inflammatory markers like IL-1β, gas bubble formation, and well-being metrics. In critical illness, gelsolin levels collapse, causing adverse outcomes.